Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Evoke Pharma, Inc. (EVOK)
Last evoke pharma, inc. earnings: 11/7 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
evokepharmainc.gcs-web.com/investor-overview
Company Research
Source: Yahoo! Finance
Net product sales for the third quarter of 2025 reached $4.3 million; up 61% year-over-year Gimoti patent life for Gimoti extended through November 2038 SOLANA BEACH, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “The proposed transaction with QOL Medical reflects this progress and the strategic value we've built around GIMOTI and across the broader GI community,” commented Matt D'Onofrio, Chief Executive Officer of Evoke Pharma. “We are proud of the consistent execution that led to another quarter of strong sales growth, with net product sales up over 60% year-over-year,” D'Onofrio added. Third Quarter 2025 Highlights and Recent Developments On November 4, 2025, Evoke announced that
Show less
Read more
Impact Snapshot
Event Time:
EVOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVOK alerts
High impacting Evoke Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
EVOK
News
- Halper Sadeh LLC Encourages EVOK, FSFG, BRY Shareholders to Contact the Firm to Discuss Their RightsGlobeNewswire
- Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAIPR Newswire
- Evoke Pharma GAAP EPS of -$0.45, revenue of $4.28M [Seeking Alpha]Seeking Alpha
- Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire
EVOK
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/17/25 - Form SC
- 11/17/25 - Form SC
- EVOK's page on the SEC website